ApprovalTrail

Drug · DIN 01968017

NEUPOGEN

VIALS

Yes: authorized and sold in Canada

Authorized, and the company reports that it sells it in Canada.

Status Marketed since June 20, 2002; first marketed December 31, 1992.
Drug Identification Number (DIN)
01968017
Company (DIN owner)
Amgen Canada IncMississauga, Ontario, Canada
Schedule
Schedule D; Prescription
Dosage form
Solution
Route
Subcutaneous; Intravenous
Therapeutic class (ATC)
Filgrastim L03AA02
Class
Human
Record last updated
August 6, 2026

Active ingredients

As listed in the Drug Product Database.

IngredientStrengthPer
FILGRASTIM300 MCGML

Notices of Compliance

Health Canada approvals that name this DIN.

  • June 19, 2002: NOC 506New Drug Submission (NDS) · Manufacturer name change
  • October 6, 1997: NOC 3802Supplement to a New Drug Submission (SNDS) · New indication - adjunctive therapy in patients with HIV infection
  • January 16, 1997: NOC 3803Supplement to a New Drug Submission (SNDS) · Changes in manufacturing facility, including multi-use activities
  • January 14, 1997: NOC 3801Supplement to a New Drug Submission (SNDS) · Change in formulation
  • December 31, 1996: NOC 4404Supplement to a New Drug Submission (SNDS) · New indication - for cancer patients undergoing peripheral blood progenitor cell (pbpc) collection and therapy
  • March 11, 1996: NOC 4405Supplement to a New Drug Submission (SNDS) · New indication - to reduce the duration of neutropenia and neutropenia-related clinical sequelae, in patients undergoing myeloablative therapy followed by bone marrow transplantation

Recalls and safety alerts that mention it

Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “neupogen”. A notice may cover another product or only some lots: read it to see what it covers.

Other DINs named NEUPOGEN